These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32682446)

  • 1. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
    Zheng XB; Diwan VK; Zhao Q; Hu Y; Bruchfeld J; Jiang WL; Hoffner S; Xu B
    Infect Dis Poverty; 2020 Jul; 9(1):97. PubMed ID: 32682446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Chen Y; Yuan Z; Shen X; Wu J; Wu Z; Xu B
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.
    Koroma JA; Elduma AH; Sesay U; Gebru GN
    BMC Infect Dis; 2024 Jun; 24(1):579. PubMed ID: 38862873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
    Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
    J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China.
    Huang H; Ding N; Yang T; Li C; Jia X; Wang G; Zhong J; Zhang J; Jiang G; Wang S; Zong Z; Jing W; Zhao Y; Xu S; Chen F
    Clin Infect Dis; 2019 Jul; 69(3):405-413. PubMed ID: 30321294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.
    Liang L; Wu Q; Gao L; Hao Y; Liu C; Xie Y; Sun H; Yan X; Li F; Li H; Fang H; Ning N; Cui Y; Han L
    Thorax; 2012 Jul; 67(7):632-8. PubMed ID: 22403070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study.
    Huai P; Huang X; Cheng J; Zhang C; Wang K; Wang X; Yang L; Deng Z; Ma W
    Microb Drug Resist; 2016 Dec; 22(8):717-726. PubMed ID: 27058017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis.
    Yang Z; Zhou C; Ning Z; Lu W; Zhao Q; Hu Y; Diwan VK; Xu B
    Glob Health Action; 2018; 11(1):1500763. PubMed ID: 30203719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China.
    Sun Y; Harley D; Vally H; Sleigh A
    PLoS One; 2017; 12(1):e0168865. PubMed ID: 28118372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
    Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA
    Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012-2014: a retrospective cohort study.
    Thu MK; Kumar AMV; Soe KT; Saw S; Thein S; Mynit Z; Maung HMW; Aung ST
    Trans R Soc Trop Med Hyg; 2017 Sep; 111(9):410-417. PubMed ID: 29351672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.